Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 9, 2026HaemophiliaOpen Access

Beyond Standard Half‐Life: Real‐world Pharmacokinetics of Efanesoctocog Alfa in a Single Centre

View Full Paper
Ask AI
Bookmark
Share

Authors

LSLaurent SattlerAHAgathe HerbLPLéa Pierre

Discussion

Loading...

Member takes

Overview

Single-centre study reports real-world pharmacokinetics of efanesoctocog alfa in patients with haemophilia A, suggesting optimized management strategies.

Key Points

  • The aim is to report real-world pharmacokinetic data for efanesoctocog alfa in individuals with severe hemophilia A.
  • Conducted in a single centre at Strasbourg University Hospital
  • Adults and children (>6 years) with severe hemophilia A switched from prior FVIII to EFA
  • PK assessments performed post-infusion of EFA at defined intervals.
  • In adults, mean half-life was 52 h with a significant interindividual variance
  • Mean FVIII trough levels were 19 IU/dL at steady state, showing improvement from the switch
  • In children, mean half-life was 53 h and trough levels were 13-14 IU/dL.

Cite This Study

Sattler et al. (2026) studied this question.

synapsesocial.com/papers/69fed021b9154b0b82877214https://doi.org/10.1111/hae.70306
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Assay of Efanesoctocog Alfa in 200 Centres: Data Form Collaborative NEQAS BC (United Kingdom) and ECAT (Netherlands) Exercise Autumn 20242025 · 5 citations
  2. 2Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A2024 · 45 citations
  3. 3Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens2015 · 376 citations
  4. 4Quality of life and its predictors among adult patients with haemophilic arthropathy. An observational study2021 · 36 citations
  5. 5Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia2022 · 4 citations